自引率: 0.3%
被引量: 1270
通过率: 暂无数据
审稿周期: 12
版面费用: 暂无数据
国人发稿量: 暂无数据
投稿须知/期刊简介:
Each issue of Surgical Oncology Clinics reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.
期刊描述简介:
Each issue of Surgical Oncology Clinics reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.
-
The Contemporary Management of Esophageal and Gastric Cancer.
被引量：- 发表：1970
-
The Contemporary Management of Esophageal and Gastric Cancer.
被引量：- 发表：1970
-
The Impact of Racial Disparities and the Social Determinants of Health on Esophageal and Gastric Cancer Outcomes.
Reducing long-standing inequities in gastric and esophageal cancers is a priority of patients, providers, and policy makers. Many social determinants of health influence risk factors for disease development, incidence, treatment, and outcomes of gastric and esophageal cancers.
被引量：- 发表：1970
-
Immune Checkpoint Inhibitors in Esophageal Carcinoma: Assessment of Efficacy Predictors of Response in Clinical Trials.
Esophageal carcinoma (EC) is among the most common causes of cancer-related deaths worldwide. Even with the improvement of multidisciplinary treatment modalities, advanced unresectable EC patients had limited systemic therapeutic options for an extended period. Recently, immune checkpoint inhibitors (ICIs) have been introduced to advanced EC management in both first-line and second-line options, as well as in postoperative settings in resectable EC after preoperative chemoradiation. Herein, the authors present a comprehensive review of clinical trials on administering ICIs in EC patients while discussing reported clinical, molecular, and immune biomarkers and their predictive value for treatment efficacy.
被引量：- 发表：1970
-
Updates in Translational Science for Esophageal and Gastric Cancers.
In this article, the authors summarize the current state of translational science for esophageal and gastric cancers. The available targeted therapies, immunotherapies, and recently discovered molecular targets are reviewed. The authors introduce circulating tumor deoxyribonucleic acid and its promise as a biomarker to detect disease recurrence. The authors present patient-derived organoids as a new model for studying carcinogenesis and treatment responses. Finally, we discuss the implications of organoid models for precision oncology and describe exciting new work applying gene editing technology to organoids and studying tumor-microenvironment interactions using 3-dimensional co-culture systems.
被引量：- 发表：1970
